Fortress Biotech (NasdaqCM:FBIO) - Share price, News & Analysis

FBIO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

FBIO Overview

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products.

Rewards

Earnings are forecast to grow 65.77% per year

Earnings have grown 6.5% per year over the past 5 years

Risk Analysis

Shareholders have been diluted in the past year

Fortress Biotech Competitors

Becton Dickinson

NYSE:BDX

US$73.8b

Price History & Performance

Summary of all time highs, changes and price drops for Fortress Biotech
Historical stock prices
Current Share Price	US$3.44
52 Week High	US$2.12
52 Week Low	US$6.10
Beta	2.44
1 Month Change	6.17%
3 Month Change	-7.03%
1 Year Change	-10.88%
3 Year Change	135.62%
5 Year Change	20.70%
Change since IPO	-68.73%

Shareholder Returns

	FBIO	US Biotechs	US Market
7D	4.9%	0.07%	-0.5%
1Y	-10.9%	31.0%	37.5%

Return vs Industry: FBIO underperformed the US Biotechs industry which returned 28.4% over the past year.

Return vs Market: FBIO underperformed the US Market which returned 36.2% over the past year.

Price Volatility

Is FBIO's price volatile compared to industry and market?
FBIO volatility
FBIO Beta	2.44
Industry Beta	1.03
Market Beta	1

Stable Share Price: FBIO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: FBIO's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2006	111	Lindsay Rosenwald	https://www.fortressbiotech.com

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children.

Fortress Biotech Fundamentals Summary

How do Fortress Biotech's earnings and revenue compare to its market cap?
FBIO fundamental statistics
Market Cap	US$337.55m
Earnings (TTM)	-US$33.20m
Revenue (TTM)	US$52.65m

6.6x

P/S Ratio

-10.5x

P/E Ratio

Is FBIO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
FBIO income statement (TTM)
Revenue	US$52.65m
Cost of Revenue	US$39.45m
Gross Profit	US$13.20m
Expenses	US$46.40m
Earnings	-US$33.20m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.42
Gross Margin	25.08%
Net Profit Margin	-63.05%
Debt/Equity Ratio	30.2%

How did FBIO perform over the long term?

See historical performance and comparison

Valuation

Is Fortress Biotech undervalued compared to its fair value and its price relative to the market?

3.21x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate FBIO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate FBIO's fair value to establish if it is undervalued.

Price To Earnings Ratio

PE vs Industry: FBIO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: FBIO is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FBIO's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: FBIO's PB Ratio (3.2x) is in line with the US Biotechs industry average.

Future Growth

How is Fortress Biotech forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

65.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FBIO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: FBIO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: FBIO's is expected to become profitable in the next 3 years.

Revenue vs Market: FBIO's revenue (29.9% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: FBIO's revenue (29.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if FBIO's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Fortress Biotech performed over the past 5 years?

6.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: FBIO is currently unprofitable.

Growing Profit Margin: FBIO is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: FBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 6.5% per year.

Accelerating Growth: Unable to compare FBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).

Return on Equity

High ROE: FBIO has a negative Return on Equity (-40.64%), as it is currently unprofitable.

Financial Health

How is Fortress Biotech's financial position?

Financial Position Analysis

Short Term Liabilities: FBIO's short term assets ($320.3M) exceed its short term liabilities ($70.6M).

Long Term Liabilities: FBIO's short term assets ($320.3M) exceed its long term liabilities ($99.3M).

Debt to Equity History and Analysis

Debt Level: FBIO's debt to equity ratio (30.2%) is considered satisfactory.

Reducing Debt: FBIO's debt to equity ratio has reduced from 37.4% to 30.2% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FBIO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: FBIO has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 17.4% each year.

Dividend

What is Fortress Biotech current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate FBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FBIO's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

7.8yrs

Average management tenure

CEO

Lindsay Rosenwald (66 yo)

7.75yrs

Tenure

US$2,636,602

Compensation

Dr. Lindsay Allan Rosenwald, M.D., serves as the Chairman of the Board of Directors at Avenue Therapeutics, Inc since February 2015. Dr. Rosenwald has been Executive Chairman, Chief Executive Officer and P...

CEO Compensation Analysis

Compensation vs Market: Lindsay's total compensation ($USD2.64M) is above average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Lindsay's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: FBIO's management team is seasoned and experienced (7.8 years average tenure).

Board Members

Experienced Board: FBIO's board of directors are considered experienced (7.6 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.8%.

Data	Last Updated (UTC time)
Company Analysis	2021/09/23 23:05
End of Day Share Price	2021/09/23 00:00
Earnings	2021/06/30
Annual Earnings	2020/12/31

Market Cap

7D

1Y

Updated

Data